Thus, SurVaxM, a peptide mimetic survivin vaccine tested in combination with TMZ in newly diagnosed GBM, was found to be safe and produced survivin-specific CD8+ T cells and antibodies in a phase 2 clinical trial (174). The gene discussed is BIRC5; the disease is glioblastoma.